GlassScriptPhysician profile
Mohammad A Zia
NPI 1679570139
$2,961.40
in general payments reported to CMS, 2019-2025
23 companies · $663 in 2025
The $663 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $315 · 2020: $114 · 2021: $299 · 2022: $424 · 2023: $410 · 2024: $737 · 2025: $663.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,810.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,809.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $598.89 | 2019-2024 | Veltassa |
| Astrazeneca Pharmaceuticals LP | $560.28 | 2019-2025 | Lokelma, Farxiga |
| Mallinckrodt Hospital Products INC. | $251.76 | 2020-2025 | Acthar, Terlivaz |
| Travere Therapeutics, INC. | $218.59 | 2023-2025 | |
| Calliditas Therapeutics US INC. | $213.60 | 2022-2025 | Tarpeyo |
| Ardelyx, INC. | $161.08 | 2023-2025 | Ibsrela |
| Novartis Pharmaceuticals Corporation | $153.95 | 2023-2025 | |
| Lilly USA, LLC | $144.16 | 2024-2025 | Jardiance |
| Fresenius USA Marketing, INC. | $85.32 | 2019-2021 | |
| Horizon Therapeutics Plc | $82.24 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $75.34 | 2021-2025 | |
| Amgen INC. | $67.77 | 2024 | Krystexxa, Tavneos |
| Akebia Therapeutics INC | $51.10 | 2019-2025 | Vafseo |
| Otsuka America Pharmaceutical, INC. | $43.53 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.37 | 2023-2024 | Jardiance |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $36.08 | 2021-2023 | |
| Glaxosmithkline, LLC. | $36.01 | 2022-2023 | Benlysta |
| Cormedix INC. | $32.79 | 2024 | Defencath |
| Outset Medical INC | $30.31 | 2023 | |
| Amicus Therapeutics, INC. | $28.35 | 2020-2021 | |
| Aurinia Pharma U.S., INC. | $21.35 | 2024 | Lupkynis |
| Janssen Pharmaceuticals, INC | $21.11 | 2021 | |
| Mallinckrodt Enterprises LLC | $11.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Zia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.